The Lymphoma Hub was pleased to speak to Grzegorz S. Nowakowski, Mayo Clinic, Rochester, US, who discussed the real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL.
On June 6, 2025, the European Commission approved fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, for the treatment of adult patients with previously untreated…
On June 4, 2025, the FDA granted Breakthrough Therapy Designation for iopofosine I 131 for the treatment of relapsed/refractory Waldenstrom’s macroglobulinemia.
On June 3, 2025, the European Commission approved brentuximab vedotin, in combination with ECADD chemotherapy, for adult patients with newly diagnosed Stage IIb with risk…
New data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
The Lymphoma Hub was pleased to speak to Grzegorz S. Nowakowski, Mayo Clinic, Rochester, US, who discussed the real-world experience of tafasitamab and lenalidomide for…
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Stay up to date with the latest developments in lymphoma and CLL with the Lymphoma Hub’s live social media coverage from the 2025 ASCO Annual…
New data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Stay up to date with the latest developments in lymphoma and CLL with the Lymphoma Hub’s live social media coverage from the 2025 ASCO Annual…
